stockrowTeva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) EBITDA
Teva Pharmaceutical Industries Ltd.'s EBITDA for fiscal 2025 was $3.2B, up 55.2% from $2.0B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.3B. Over the past ten years it has ranged from −$15.4B (fiscal 2017) to $4.7B (fiscal 2015); the current reading is higher than 73% of that period. EBITDA has risen for 3 consecutive fiscal years. Teva Pharmaceutical Industries Ltd. ranks 5th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $3.2B | 55.21% |
| FY2024 | $2.0B | 28.37% |
| FY2023 | $1.6B | — |
| FY2022 | −$889.0M | — |
| FY2021 | $3.0B | — |
| FY2020 | −$2.0B | — |
| FY2019 | $1.3B | (60.46%) |
| FY2018 | $3.2B | — |
| FY2017 | −$15.4B | — |
| FY2016 | $3.7B | (21.07%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $959.0M | 510.83% |
| Jun 2026 | $157.0M | (82.38%) |
| Mar 2026 | $891.0M | 171.65% |
| Dec 2025 | $328.0M | (70.97%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $8.3B |
| HLN Haleon PLC Sponsored ADR compare | $4.3B |
| ZTS Zoetis Inc. compare | $4.0B |
| VTRS Viatris Inc. compare | $2.7B |
| TEVA Teva Pharmaceutical Industries Ltd. | $2.3B |
| UTHR United Therapeutics Corporation compare | $1.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $976.5M |
| ELAN Elanco Animal Health Incorporated compare | $774.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on TEVA
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement